Our client, Sanofi-Aventis, has obtained FDA approval for its new atrial fibrillation/atrial flutter treatment, MULTAQ. The product is expected to be available later this summer.
Congratulations to Sanofi-Aventis!
Posted in Trademarks | No Comments »
Lombard & Geliebter, LLP – The Blog is proudly powered by
and Comments (RSS).